Europe Glucagon-Like Peptide-1 Agonists Industry Leaders Novo Nordisk AstraZeneca Eli lilly and Company Sanofi Pfizer *Disclaimer: Major Players sorted in no particular order Recent Industry Developments April 2023: Eli Lilly and Company and Amphastar Pharmaceuticals, Inc
As the results of most genetic studies related to the polymorphisms mentioned above were inconsistent and mainly carried out in patients of European descent, the authors were interested in exploring the potential genetic association of the selected 12 SNPs with obesity in a sample of the Middle Eastern population and relating the different genotypes with the available clinic-laboratory data
M., Pfeiffer, A., Birkenfeld, A
Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery
Although they work in the same way, Ozempic and Mounjaro are different medications with different active ingredients, so it isnt accurate to compare their dose strengths